Expansion of Particle Therapy at Heidelberg University Hospital
Heidelberg University Hospital has made a significant commitment to advancing cancer treatment by integrating IBA's cutting-edge ProteusONE proton therapy solution into its services. This essential upgrade will be located on the university campus, marking a notable milestone for both the hospital and IBA, a key player in particle accelerator technology.
Innovative Cancer Treatment with Proton Therapy
The ProteusONE system is a state-of-the-art compact proton therapy solution designed to offer precise cancer treatments. Heidelberg University Hospital has been providing particle therapy since 2010, making it a leader in the field. With this new addition, UKHD aims to enhance patient care with more targeted and effective treatment methods.
Strategic Benefits for Patients
The inclusion of the ProteusONE system is poised to elevate the quality of care provided to cancer patients, ensuring they have access to the most advanced treatment options available. As healthcare evolves, so does the need for innovative solutions that focus on patient outcomes.
Significant Steps in the Contract
The formal agreement between IBA and Heidelberg University Hospital signifies a long-term partnership, which includes operational and maintenance agreements that span several years. This commitment not only reflects IBA's esteemed position in particle therapy but also UKHD's dedication to excellence in patient care. They anticipate welcoming their first patients for treatment in the latter part of the decade.
Expert Perspectives on the Collaboration
Olivier Legrain, IBA's CEO, expressed his enthusiasm about partnering with such a prestigious institution. He noted the collaboration's potential to bring state-of-the-art technology to improve the lives of patients throughout Germany.
Financial Insights
The investment in the ProteusONE system is substantial, with pricing typically ranging between EUR 35 million and EUR 45 million for the unit and associated multi-year support contracts. This investment underscores UKHD's intention to remain at the forefront of cancer treatment.
About IBA and its Mission
IBA stands as a global leader in particle accelerator technology, specializing not just in proton therapy, but also in radiopharmaceuticals and industrial sterilization. The company prides itself on a strong workforce and is recognized for its commitment to social and environmental responsibility, functioning as a certified B Corporation.
About Heidelberg University Hospital
Founded over 600 years ago, Heidelberg University Hospital is a prominent medical center renowned for its quality care and advanced research in precision medicine. The institution continues to advance its capabilities, especially in radiation oncology, ensuring a bright future for both the hospital and its patients.
Frequently Asked Questions
What is the ProteusONE system?
The ProteusONE system is a compact proton therapy solution designed to deliver targeted cancer treatment.
How will this expansion affect patient care?
This expansion increases access to advanced treatment options, ensuring patients receive cutting-edge cancer therapy.
What is the estimated cost of the ProteusONE system?
The estimated cost for the ProteusONE system, along with maintenance contracts, typically ranges from EUR 35 million to EUR 45 million.
When does UKHD plan to start treating patients with the new system?
UKHD expects to begin patient treatments in the latter half of the decade.
What is IBA's focus as a company?
IBA focuses on providing advanced particle accelerator technologies, particularly in proton therapy, to improve cancer treatment outcomes.
